Abstract
In some countries, including Sweden, no risk is considered to exist with the use of meclozine for nausea and vomiting in pregnancy (NVP), but in other countries warnings against use during pregnancy are given. Rat tests indicate a teratogenic risk and published epidemiological studies are of restricted size. Delivery outcome was studied in 16,536 women who reported the use of meclozine in early pregnancy and was compared with all 540,660 women who gave birth. Information on drug usage was obtained prospectively in early pregnancy. Risk factors for using meclozine were young maternal age, to have had a previous child, not to smoke, to have a low body mass index. The use of some other drugs (antihypertensives, thyroxine, anticonvulsants) decreased the use of meclozine. Maternal diagnoses of preeclampsia or diabetes were less frequent when the woman had used meclozine. The twinning rate was increased and the sex distribution of the infants low (female excess). Preterm birth, low birth weight, short body length, and small head circumference occurred at a reduced rate after meclozine use, notably for boys. Also the rate of congenital malformations was reduced. If anything, delivery outcome is better than expected when the mother used meclozine. These beneficial effects are probably secondary to NVP. Meclozine can apparently be used without risk at this condition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
King CT. Teratogenic effect of meclizine hydrochloride on the rat. Science 1983; 141: 353–355.
Giurges M, Pudgdevall J. Experimental teratology with meclozine. Med Exp 1966; 15: 375–388.
Nelson MM, Forfar JO. Association between drug administration during pregnancy and congenital abnormalities of the fetus. Br Med J 1971; i: 523–527.
Greenberg G, Inman WhW, Weatherall JAC, Adelskin AM, Haskey JC. Maternal drug history and congenital abnormalities. Br Med J 1977; ii: 853–856.
Shapiro S, Kaufman DW, Rosenberg L, et al. Meclizine in pregnancy in relation to congenital malformations. Br Med J 1978; i: 483.
Milkovich L, van der Berg BJ. An evaluation of the teratogenicity of certain antinauseant drug. Am J Obst Gynecol 1983; 125: 244–248.
Cnattingius S, Ericson A, Gunnarskog J, Källén B. A quality study of a medical birth registry. Scand J Soc Med 1990; 18: 143–148.
Källén B. Search for teratogenic risks with the aid of malformation registries. Teratology 1987; 35: 47–52.
Källén B. A birth weight for gestational age standard based on data in the Swedish Medical Birh Registry, 1985-1989. Eur J Epidemiol 1995; 11: 601–606.
Yerushalmy J, Milkovich L. Evaluation of the teratogenic effect of meclizine in man. Am J Obst Gynecol 1965; 93: 553–562.
Kullander S, Källén B. A prospective study of drugs and pregnancy. II. Antiemetic drugs. Acta Obst Gynecol Scand 1976; 55:105–111.
Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: A prospective study of its frequency, intensity, and patterns of change. Am J Obst Gynecol 2000; 182: 931–937.
Clausson B, Granath F, Ekbom A, et al. Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol 2002; 158: 429–436.
Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: Meta-analysis. Am J Perinatol 1994; 14: 119–124.
Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obst Gynecol 2002; 186(Suppl 2): 256–261.
Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002; 11: 146–152.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Källén, B., Mottet, I. Delivery outcome after the use of meclozine in early pregnancy. Eur J Epidemiol 18, 665–670 (2003). https://doi.org/10.1023/A:1024891618953
Issue Date:
DOI: https://doi.org/10.1023/A:1024891618953